Study identifier:D2750C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2008-006747-39
CTIS identifier:N/A
Open label Positron Emission Tomography study with [18F]AZD4694 and [11C]AZD2184, candidate radioligands for AB amyloid, to determine and compare in vivo brain uptake and distribution in healthy volunteers and patients with Alzheimer's Disease
Alzheimer's disease
Phase 1
Yes
radioligand [18F]AZD4694, radioligand [11C]AZD2184
All
26
Interventional
50 Years - 85 Years
Allocation: Non-randomized
Endpoint Classification: N/A
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Oct 2009 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The study is carried out in order to investigate if [18F]AZD4694, compared to [11C]AZD2184, is a suitable PET ligand for in vivo imaging of Aβ amyloid depositions in the human brain. In the study the two PET ligands will be examined in both healthy volunteers and patients with Alzheimer's Disease. A whole body dosimetry scanning will be performed in 6 healthy volunteers to obtain human data to estimate a safe dose.
Location
Location
HUDDINGE, Sweden
Location
STOCKHOLM, Sweden
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: radioligand [18F]AZD4694 single dose of iv. admin. 1-2 times per subject Drug: radioligand [11C]AZD2184 single dose of iv admin. 1 time per subject |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.